Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...
As Stacey Leasca reports for “Food & Wine,” research from Cornell University found that households with at least one GLP-1 ...
FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...
A large study published in Nature Medicine reviewed the effects of GLP-1 drugs like Ozempic and Mounjaro on 175 different ...
Snack foods and sweet treats have seen a decline in purchases, as people reach for more nutrient-dense options.
A comprehensive new study confirmed that GLP-1 medications such as Ozempic and Mounjaro have myriad health benefits — even more than previously thought. Analyzing the medical records of roughly ...
Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the ...
Josh Gad is opening up about the weight loss success he’s had with GLP-1 medication — and sharing some of the conflicted ...
In all, researchers found that people taking GLP-1 medications had lower risks for 42 health outcomes, including liver ...
When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...
As GLP-1 medications like Ozempic, Wegovy, Zepbound, and Mounjaro gain popularity, doctors are observing a surge in patients ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback